News
NVS
97.81
-1.27%
-1.26
Diving Into Deciphera Pharmaceuticals
Shares of Deciphera Pharmaceuticals, Inc. Have rallied 40% since October after positive trial data for vimseltinib in the treatment of TGCT. Vimsel tinib is expected to make significant progress in the TGCT indication. The company's switch-control kinase inhibitor platform aims to produce compounds that target specific regions of kinases.
Seeking Alpha · 8h ago
These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)
Annual Meeting of the American Society of Clinical Oncology will be held in Chicago. The oral presentations will cover a range of topics including targeted therapies and immunologic therapies for various types of cancer. The plenary session will feature presentations on esophageal cancer, melanoma and lung cancer.
Seeking Alpha · 1d ago
Cigna to offer Humira rivals with $0 copay at specialty pharmacy
Cigna to offer close copies of AbbVie's arthritis drug Humira with $0 copay at specialty pharmacy beginning in June. The company will stock biosimilar versions of the drug at its Accredo pharmacy in the U.S. Cigna says the move should save eligible patients $3,500 per year. Abbvie has held onto 98% of the Humira market.
Reuters · 1d ago
What's Going On With Pfizer Stock On Thursday?
GSK Plc has reportedly taken legal action against Pfizer Inc and BioNTech SE in a Delaware federal court. The lawsuit alleges patent infringement concerning mRNA technology used in the COVID-19 vaccines. GSK says its patents underpin the technology used to develop the vaccines. Pfizer says it will defend against GSK's claims.
Benzinga · 1d ago
Novartis Pharms Corp Gets FDA New Drug Application Approval For VIJOICE
Benzinga · 1d ago
UPDATE 3-GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology. Company accuses them of infringing GSK patents related to messenger RNA technology in the companies' blockbuster vaccines. GSK says the vaccines violate the company's patent rights in mRNA-vaccine innovations.
Reuters · 1d ago
Novartis Price Target Raised to $116.00/Share From $114.00 by BMO Capital
Dow Jones · 2d ago
Novartis Is Maintained at Market Perform by BMO Capital
Dow Jones · 2d ago
BMO Capital Maintains Market Perform on Novartis, Raises Price Target to $116
Benzinga · 2d ago
Company News for Apr 24, 2024
NASDAQ · 2d ago
UPDATE 1-Biogen beats quarterly profit estimates, Alzheimer's drug sales jump
Biogen beats quarterly profit estimates, Alzheimer's drug sales jump. The company's shares up 4% before the bell. Biogen has cut jobs and abandoned controversial drug Aduhelm to boost growth. Company says its new drug Leqembi recorded global sales of about $19 million.
Reuters · 2d ago
Novartis And Medicines For Malaria Venture Announced Data From Phase 2/3 CALINA Study, Demonstrating That Formulated Coartem Developed For Babies Weighing Less Than 5Kg With Malaria Has The Required Pharmacokinetic Profile, Good Efficacy, And Safety
Benzinga · 2d ago
EUROPE RESEARCH ROUNDUP-Akzo Nobel, Galp, Randstad
Analysts revise their ratings and price targets on several European companies. Akzo Nobel, Galp and Randstad among those revised. Adidas, AB Foods and AB Foods raise their targets for the day. Randstad and RBC raise to outperform from sector perform in their reports.
Reuters · 2d ago
FDA Approves Novartis' Lutathera For Pediatric Gastroenteropancreatic Neuroendocrine Tumors
NASDAQ · 3d ago
Why Novartis Stock Topped the Market on Tuesday
Novartis beat analyst estimates for its first quarter and raised guidance for 2024. The pharmaceutical company's stock price rose 2.27% on Tuesday. The shares did better than the S&P 500 index. The company boosted net sales by 11% year over year to $11.8 billion.
The Motley Fool · 3d ago
FDA Approves Novartis' Lutathera As First Therapy For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors
Novartis receives FDA approval for its Lutathera for pediatric patients 12 years and older with gastroenteropancreatic neuroendocrine tumors. This is the first therapy approved for use in pediatric patients with GEP-NETs. Novartis is a subsidiary of Swiss drug giant Roche.
Benzinga · 3d ago
UPDATE 1-Novartis accused of promoting asthma drug for preterm labor despite brain risk
Novartis accused of promoting asthma drug for preterm labor despite brain risk. People with autism and their mothers say drug could cause abnormal fetal brain development. Lawsuit alleges that a professor helped Novartis promote terbutaline for the dangerous off-label use. The drugmaker says it is reviewing the complaint.
Reuters · 3d ago
Novartis wins pediatric indication for Lutathera for rare cancer
Novartis wins pediatric indication for Lutathera for rare cancer. Swiss pharma said the approval marks the first for a medicine for children with this type of cancer. The U.S. FDA has approved the drug for children 12 years and older with neuroendocrine tumors.
Seeking Alpha · 3d ago
Novartis Gets FDA Approval for Lutathera in Pediatric Treatment
Novartis says FDA has approved its Lutathera therapy as a treatment for pediatric patients with certain tumors. The Swiss company says it is the first therapy approved for use in pediatric patients. The therapy is approved for the treatment of patients aged 12 and older with certain tumours.
Dow Jones · 3d ago
Stocks Rally On Weaker PMI Data, Tech Earnings Optimism, Dollar Falls: What's Driving Markets Tuesday?
The S&P 500 rose 1.2% in midday trading on Tuesday, its best performance in over a month. The Nasdaq 100 outperformed the broader market, up 1.5%. Economic data indicated a deceleration in private sector growth in April. Fears for a potential Federal Reserve rate cut by the end of the summer jumped to 72% from 67% on Monday.
Benzinga · 3d ago
More
Webull provides a variety of real-time NVS stock news. You can receive the latest news about Novartis through multiple platforms. This information may help you make smarter investment decisions.
About NVS
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.